Strategic Fluorination to Achieve a Potent, Selective, Metabolically Stable, and Orally Bioavailable Inhibitor of CSNK2
The host kinase casein kinase 2 (CSNK2) has been proposed to be an antiviral target against β-coronaviral infection. To pharmacologically validate CSNK2 as a drug target in vivo, potent and selective CSNK2 inhibitors with good pharmacokinetic properties are required. Inhibitors based on the pyrazolo[1,5-<i>a</i>]pyrimidine scaffold possess outstanding potency and selectivity for CSNK2, but bioavailability and metabolic stability are often challenging. By strategically installing a fluorine atom on an electron-rich phenyl ring of a previously characterized inhibitor <b>1</b>, we discovered compound <b>2</b> as a promising lead compound with improved in vivo metabolic stability. Compound <b>2</b> maintained excellent cellular potency against CSNK2, submicromolar antiviral potency, and favorable solubility, and was remarkably selective for CSNK2 when screened against 192 kinases across the human kinome. We additionally present a co-crystal structure to support its on-target binding mode. In vivo, compound <b>2</b> was orally bioavailable, and demonstrated modest and transient inhibition of CSNK2, although antiviral activity was not observed, possibly attributed to its lack of prolonged CSNK2 inhibition.
Authors
- Marcia K. Sanders (ORCID: https://orcid.org/0000-0002-0931-7560)
- Tammy M. Havener (ORCID: https://orcid.org/0000-0002-4613-0498)
- Mark T. Heise (ORCID: https://orcid.org/0000-0001-5829-8477)
- Alison Donnelly Axtman (ORCID: https://orcid.org/0000-0003-4779-9932)
- Han Wee Ong (ORCID: https://orcid.org/0000-0003-3232-2373)
- Rebekah J. Dickmander (ORCID: https://orcid.org/0000-0002-5367-6587)
- Xuan Yang (ORCID: https://orcid.org/0000-0001-6818-158X)
- Nathaniel J. Moorman (ORCID: https://orcid.org/0000-0003-4952-6858)
- Jason W. Brown
- Rafael M. Couñago (ORCID: https://orcid.org/0000-0003-1847-5090)
- Sharon Taft-Benz (ORCID: https://orcid.org/0000-0002-0965-8760)
- Edcon Chang (ORCID: https://orcid.org/0000-0001-9534-0291)
- David H. Drewry (ORCID: https://orcid.org/0000-0001-5973-5798)
- Stefanie Howell (ORCID: https://orcid.org/0000-0003-3392-2848)
- Timothy M. Willson (ORCID: https://orcid.org/0000-0003-4181-8223)
- Jeffery L. Smith (ORCID: https://orcid.org/0000-0003-2189-0420)
- Andreas Krämer (ORCID: https://orcid.org/0000-0003-3294-2660)
Institutions
- University of North Carolina at Chapel Hill (US)
- Goethe University Frankfurt (DE)
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Takeda (United States) (US)
Publication Details
- Journal
- Molecules
- Published
- 2024-09-02
- DOI
- https://doi.org/10.3390/molecules29174158
- Citations
- 2
- Primary Topic
- Protein Tyrosine Phosphatases
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Pfizer
- Bayer
- Merck KGaA